Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double blind, placebo controlled study

Neurogastroenterology and Motility

Volumn 29, Issue 2, 2017, Pages

  Azpiroz, F ^a,b   Dubray, C ^c   Bernalier Donadille, A ^d   Cardot, J M ^c   Accarino, A ^a,b   Serra, J ^a,b   Wagner, A ^e   Respondek, F ^e   Dapoigny, M ^f  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSERM   (France)

^d Clermont Ferrand Research Centre   (France)

^e Service Innovation   (France)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

anxiety; fibers; fructooligosaccharides; irritable bowel syndrome; microbiota

Indexed keywords

FRUCTOSE OLIGOSACCHARIDE; PLACEBO; SHORT CHAIN FRUCTOOLIGOSACCHARIDE; UNCLASSIFIED DRUG; OLIGOSACCHARIDE; VOLATILE FATTY ACID;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANXIETY; ANXIETY ASSESSMENT; ARTICLE; CLINICAL OUTCOME; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FECES MICROFLORA; FEMALE; HUMAN; HYPERSENSITIVITY; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RECTAL HYPERSENSITIVITY; RECTUM DISEASE; CLINICAL TRIAL; DRUG EFFECTS; FECES; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANXIETY; DOUBLE-BLIND METHOD; FATTY ACIDS, VOLATILE; FECES; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MICROBIOTA; MIDDLE AGED; OLIGOSACCHARIDES; TREATMENT OUTCOME;

EID: 84979732945     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12911     Document Type: Article

References (47)

1. Fukudo S, Kaneko H, Akiho H, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol. 2015;50:11–30.
2. Ohman L, Tornblom H, Simren M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol. 2015;12:36–49.
3. Kerckhoffs APM, Samsom M, van der Rest ME, et al. Lower Bifidobacteria counts in both duodenal mucose-associated and faecal microbiota in irritable bowel syndrome patients. World J Gastroenterol. 2009;15:2887–2892.
4. Ponnusamy K, Choi JN, Lee SY, Lee CH. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol. 2011;60:817–827.
5. Moloney RD, Johnson AC, O'Mahony SM, Dinan TG, Greenwood-Van Meerveld B, Cryan JF. Stress and the microbiota-gut-brain axis in visceral pain: relevance to irritable bowel syndrome. CNS Neurosci Ther. 2016;22:102–117.
6. Bouhnik Y, Flourie B, Riottot M, et al. Effects of fructo-oligosaccharides ingestion on fecal Bifidobacteria and selected metabolic indexes of colon carcinogenesis in healthy humans. Nutr Cancer. 1996;26:21–29.
7. Bouhnik Y, Raskine L, Simoneau G, Paineau D, Bornet F. The capacity of short-chain fructo-oligosaccharides to stimulate fecal Bifidobacteria: a dose-response relationship study in healthy humans. Nutr J. 2006;5:8.
8. Hidaka H, Eida T, Takizawa T, Tokunaga T, Tashiro Y. Effects of fructo-oligosaccharides on intestinal flora and human health. Bifidobacteria Microflora. 1986;5:37–50.
9. Tokunaga T, Nakada Y, Tashiro Y, Hirayama M, Hidaka H. Effects of fructooligosaccharides (FOS) intake on the intestinal microflora and defecation in healthy volunteers. Bifidus. 1993;6:143–150.
10. Rycroft CE, Jones MR, Gibson GR, Rastall RA. A comparative in vitro evaluation of the fermentation properties of prebiotic oligosacharides. J Appl Microbiol. 2001;91:878–887.
11. Boutron-Ruault MC, Marteau P, Lavergne-Slove A, et al. Effects of a 3-mo consumption of short-chain fructo-oligosaccharides on parameters of colorectal carcinogenesis in patients with or without small large colorectal adenomas. Nutr Canc. 2005;53:160–168.
12. Paineau D, Payen F, Panserieu S, et al. The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr. 2008;99:311–318.
13. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377–1390.
14. Distrutti E, Azpiroz F, Soldevilla A, Malagelada J-R. Gastric wall tension determines perception of gastric distension. Gastroenterology. 1999;116:1035–1042.
15. Distrutti E, Salvioli B, Azpiroz F, Malagelada JR. Rectal function and bowel habit in irritable bowel syndrome. Am J Gastroenterol. 2004;99:131–137.
16. Caldarella MP, Azpiroz F, Malagelada J-R. Selective effects of nutrients on gut sensitivity and reflexes. Gut. 2007;56:37–42.
17. Aspiroz F. Intestinal perception: mechanisms and assessment. Brit J Nutr. 2005;93:S7–S12.
18. Lewis S, Heaton K. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920–924.
19. Zigmond AS, Snaith RP. The Hospital Anxiety Depression scale. Acta Psychiatr Scand. 1983;67:361–370.
20. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395–402.
21. Chassard D, Dapoigny M, Scott KP, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther. 2012;35:828–838.
22. Crouzet L, Gaultier E, Del'Homme C, et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil 2013; 25: 272–282.
23. Saulnier DMA, Gibson GR, Kolida S. In vitro effects of selected synbiotics on the human faecal microbiota composition. FEMS Microbiol Ecol. 2008;66:516–527.
24. Edwards JE, Huws SA, Kim EJ, Kingston-Smith AH. Characterization of the dynamics of initial bacterial colonization of nonconserved forage in the bovine rumen. FEMS Microbiological Ecology. 2007;62:323–335.
25. Matsuki T, Watanabe K, Fujimoto J, et al. Quantitative PCR with 16S rRNA-gene-targeted species-specific primers for analysis of human intestinal Bifidobacteria. Appl Environ Microbiol. 2004;70:167–173.
26. Furet JP, Firmesse O, Gourmelon M, et al. Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol Ecol. 2009;68:351–362.
27. Bartosch S, Fite A, Macfarlane GT, McMurdo MET. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. Appl Environ Microbiol. 2004;70:3575–3581.
28. Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr. 2009;101:541–550.
29. Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792–1801.
30. Maukonen J, Satokari R, Mattö J, Söderlund H, Mattila-Sandholm T, Saarela M. Prevalence and temporal stability of selected clostridal groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol. 2006;55:625–633.
31. Mattö J, Maunuksela L, Kajander K, et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol. 2005;43:213–222.
32. Roberfroid MB, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104: 111–111.
33. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:512–519.
34. Vanhoutvin SALW, Troost FJ, Kilkens TOC, et al. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil. 2009;21:e952–e976.
35. Messaoudi M, Lalonde R, Violle N, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011;105:755–764.
36. Silk DBA, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:508–518.
37. Jalanka-Tuovinen J, Salonen A, Nikkila J, et al. Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS ONE. 2011;6:e23035.
38. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer E. Altered rectal sensitivity is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995;109:40–52.
39. Delvaux M. Do we need to perform rectal distension tests to diagnose IBS in clinical practice? Gastroenterology. 2002;122:2075–2078.
40. Posserud I, Syrous A, Lindström L, Tack J, Abrahamsson H, Simren M. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology. 2007;133:1113–1123.
41. Van der Veek PP, Van Rood YR, Masclee AA. Symptom severity but no psychopathology predicts visceral hypersensitivity in irritable bowel syndrome. ClinGastroenterol Hepatol. 2008;6:321–328.
42. Respondek F, Gerard P, Bossis M, et al. Short-chain fructo-oligosaccharides modulate intestinal microbiota and metabolic parameters of humainzed gnotobiotic diet induced obesity mice. PLoS ONE. 2013;8:e71026.
43. Le Blay G, Michel C, Blottière HM, Cherbut C. Prolonged intake of fructo-oligosaccharides induces a short-term elevation of lactic acid-producing bacteria and a persistent increase in caecal butyrate in rats. J Nutr. 1999;129:2231–2235.
44. Tsukahara T, Iwasaki Y, Nakayama K, Ushida K. Stimulation of butyrate production in the large intestine of weaning piglets by dietary fructooligosaccharides and its influence on the histological variables of the large intestinal mucosa. J Nutr Sci Vitaminol. 2003;49:414–421.
45. Bourdu S, Dapoigny M, Chapuy E, et al. Rectal instillation of butyrate provides a novel clinically relevant model of non-inflammatory hypersensitivity in rats. Gastroenterology. 2005;128:1996–2008.
46. Bouin M, Plourde V, Boivin M, et al. Rectal distension testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology. 2002;122:1771–1777.
47. Tominaga S, Hirayama M, Adachi T, Tokunaga T, Iino H. Effects of ingested fructooligosaccharides on stool frequency in healthy female volunteers: a placebo-controlled study. Bifidobacteria Microflora. 1999;18:49–53.